AlastairMarkThompsonMD

Summary

• I trained and have practiced in the United Kingdom (UK) and, since 2014, in the United States as a clinician scientist focused on multidisciplinary patient care, alongside translational “bench to bedside” studies and innovative clinical trials in cancer. I initiated and led a successful breast cancer laboratory program, provided leadership for a cancer center in the UK and chaired the UK national breast cancer trials portfolio of 120 studies. I engaged in a range of pivotal roles in key drug, radiation therapy and surgical trials involving the UK, Europe, the US and Australia. Since moving to the US in 2014, I have specialized clinically in improving treatment for breast cancer patients with innovative surgical techniques.
  Unusually for a surgeon, I have preclinical and practical experience in the design, implementation, monitoring and reporting of early through to late phase drug and medical device trials. I currently chair several phase II and phase III data monitoring committees and trials steering groups. Since transitioning to the US, national leadership roles include the Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for low risk DCIS; member and now co-chair of the NCI BOLD taskforce; leadership positions within TBCRC (Loco-regional Subgroup co-Chair) and SWOG (Translational Medicine Breast Group Chair). I am an active member of ASCO, AACR, SSO and ASBrS. I have over 400 peer reviewed publications in the highest impact factor clinical and scientific journals, successful supervision to completion of 24 postgraduate PhD/research MD students, peer reviewed funding from US government and international charitable sources,
  As Chairman of a 15,000 patient prospective cohort study of screen detected preinvasive breast neoplasia (the Sloane Project) for the last two decades, I focus on the patterns of care and underlying molecular changes in Ductal Carcinoma in situ (DCIS) and atypias offer the opportunity to reduce overtreatment of these no